Persons with dispensed medicines; age and sex
| Sex | Ages | Medicine group (ATC) | Periods | Persons with medicines, relative (%) |
|---|---|---|---|---|
| Total male and female | Total age | Total | 2006 | 67.54 |
| Total male and female | Total age | Total | 2010 | 70.05 |
| Total male and female | Total age | Total | 2015 | 66.26 |
| Total male and female | Total age | Total | 2020 | 62.80 |
| Total male and female | Total age | Total | 2021 | 63.33 |
| Total male and female | Total age | Total | 2022 | 63.99 |
| Total male and female | Total age | Total | 2023* | 64.01 |
| Total male and female | Total age | A Alimentary tract and metabolism | 2006 | 18.79 |
| Total male and female | Total age | A Alimentary tract and metabolism | 2010 | 23.94 |
| Total male and female | Total age | A Alimentary tract and metabolism | 2015 | 23.47 |
| Total male and female | Total age | A Alimentary tract and metabolism | 2020 | 24.24 |
| Total male and female | Total age | A Alimentary tract and metabolism | 2021 | 24.94 |
| Total male and female | Total age | A Alimentary tract and metabolism | 2022 | 24.87 |
| Total male and female | Total age | A Alimentary tract and metabolism | 2023* | 21.61 |
| Total male and female | Total age | A10 Drugs used in diabetes | 2006 | 3.76 |
| Total male and female | Total age | A10 Drugs used in diabetes | 2010 | 4.38 |
| Total male and female | Total age | A10 Drugs used in diabetes | 2015 | 4.67 |
| Total male and female | Total age | A10 Drugs used in diabetes | 2020 | 4.65 |
| Total male and female | Total age | A10 Drugs used in diabetes | 2021 | 4.74 |
| Total male and female | Total age | A10 Drugs used in diabetes | 2022 | 4.85 |
| Total male and female | Total age | A10 Drugs used in diabetes | 2023* | 5.04 |
| Total male and female | Total age | B Blood and blood forming organs | 2006 | 10.41 |
| Total male and female | Total age | B Blood and blood forming organs | 2010 | 11.54 |
| Total male and female | Total age | B Blood and blood forming organs | 2015 | 12.34 |
| Total male and female | Total age | B Blood and blood forming organs | 2020 | 12.85 |
| Total male and female | Total age | B Blood and blood forming organs | 2021 | 13.12 |
| Total male and female | Total age | B Blood and blood forming organs | 2022 | 13.22 |
| Total male and female | Total age | B Blood and blood forming organs | 2023* | 13.33 |
| Total male and female | Total age | B01 Antithrombotic agents | 2006 | 8.27 |
| Total male and female | Total age | B01 Antithrombotic agents | 2010 | 9.34 |
| Total male and female | Total age | B01 Antithrombotic agents | 2015 | 10.07 |
| Total male and female | Total age | B01 Antithrombotic agents | 2020 | 10.43 |
| Total male and female | Total age | B01 Antithrombotic agents | 2021 | 10.61 |
| Total male and female | Total age | B01 Antithrombotic agents | 2022 | 10.64 |
| Total male and female | Total age | B01 Antithrombotic agents | 2023* | 10.72 |
| Total male and female | Total age | C Cardiovascular system | 2006 | 18.96 |
| Total male and female | Total age | C Cardiovascular system | 2010 | 21.01 |
| Total male and female | Total age | C Cardiovascular system | 2015 | 21.38 |
| Total male and female | Total age | C Cardiovascular system | 2020 | 21.18 |
| Total male and female | Total age | C Cardiovascular system | 2021 | 21.32 |
| Total male and female | Total age | C Cardiovascular system | 2022 | 21.25 |
| Total male and female | Total age | C Cardiovascular system | 2023* | 21.31 |
| Total male and female | Total age | C07 Beta blocking agents | 2006 | 8.62 |
| Total male and female | Total age | C07 Beta blocking agents | 2010 | 9.68 |
| Total male and female | Total age | C07 Beta blocking agents | 2015 | 9.46 |
| Total male and female | Total age | C07 Beta blocking agents | 2020 | 8.73 |
| Total male and female | Total age | C07 Beta blocking agents | 2021 | 8.68 |
| Total male and female | Total age | C07 Beta blocking agents | 2022 | 8.49 |
| Total male and female | Total age | C07 Beta blocking agents | 2023* | 8.38 |
| Total male and female | Total age | C10 Lipid modifying agents | 2006 | 8.13 |
| Total male and female | Total age | C10 Lipid modifying agents | 2010 | 9.77 |
| Total male and female | Total age | C10 Lipid modifying agents | 2015 | 11.34 |
| Total male and female | Total age | C10 Lipid modifying agents | 2020 | 11.43 |
| Total male and female | Total age | C10 Lipid modifying agents | 2021 | 11.55 |
| Total male and female | Total age | C10 Lipid modifying agents | 2022 | 11.58 |
| Total male and female | Total age | C10 Lipid modifying agents | 2023* | 11.69 |
| Total male and female | Total age | D Dermatologicals | 2006 | 20.01 |
| Total male and female | Total age | D Dermatologicals | 2010 | 21.17 |
| Total male and female | Total age | D Dermatologicals | 2015 | 19.90 |
| Total male and female | Total age | D Dermatologicals | 2020 | 17.97 |
| Total male and female | Total age | D Dermatologicals | 2021 | 18.25 |
| Total male and female | Total age | D Dermatologicals | 2022 | 18.50 |
| Total male and female | Total age | D Dermatologicals | 2023* | 18.81 |
| Total male and female | Total age | G Genito urinary system and sex hormones | 2006 | 12.18 |
| Total male and female | Total age | G Genito urinary system and sex hormones | 2010 | 15.82 |
| Total male and female | Total age | G Genito urinary system and sex hormones | 2015 | 7.49 |
| Total male and female | Total age | G Genito urinary system and sex hormones | 2020 | 6.89 |
| Total male and female | Total age | G Genito urinary system and sex hormones | 2021 | 6.93 |
| Total male and female | Total age | G Genito urinary system and sex hormones | 2022 | 6.73 |
| Total male and female | Total age | G Genito urinary system and sex hormones | 2023* | 6.59 |
| Total male and female | Total age | H Systemic hormonal prep,ex.sex hormones | 2006 | 5.66 |
| Total male and female | Total age | H Systemic hormonal prep,ex.sex hormones | 2010 | 6.49 |
| Total male and female | Total age | H Systemic hormonal prep,ex.sex hormones | 2015 | 7.47 |
| Total male and female | Total age | H Systemic hormonal prep,ex.sex hormones | 2020 | 7.21 |
| Total male and female | Total age | H Systemic hormonal prep,ex.sex hormones | 2021 | 7.34 |
| Total male and female | Total age | H Systemic hormonal prep,ex.sex hormones | 2022 | 7.59 |
| Total male and female | Total age | H Systemic hormonal prep,ex.sex hormones | 2023* | 7.77 |
| Total male and female | Total age | H03 Thyroid therapy | 2006 | 1.92 |
| Total male and female | Total age | H03 Thyroid therapy | 2010 | 2.31 |
| Total male and female | Total age | H03 Thyroid therapy | 2015 | 2.74 |
| Total male and female | Total age | H03 Thyroid therapy | 2020 | 2.98 |
| Total male and female | Total age | H03 Thyroid therapy | 2021 | 3.01 |
| Total male and female | Total age | H03 Thyroid therapy | 2022 | 3.01 |
| Total male and female | Total age | H03 Thyroid therapy | 2023* | 3.03 |
| Total male and female | Total age | J General antiinfectives for system.use | 2006 | 24.51 |
| Total male and female | Total age | J General antiinfectives for system.use | 2010 | 24.56 |
| Total male and female | Total age | J General antiinfectives for system.use | 2015 | 22.53 |
| Total male and female | Total age | J General antiinfectives for system.use | 2020 | 17.54 |
| Total male and female | Total age | J General antiinfectives for system.use | 2021 | 17.25 |
| Total male and female | Total age | J General antiinfectives for system.use | 2022 | 19.33 |
| Total male and female | Total age | J General antiinfectives for system.use | 2023* | 20.09 |
| Total male and female | Total age | J01 Antibacterials for systemic use | 2006 | 23.02 |
| Total male and female | Total age | J01 Antibacterials for systemic use | 2010 | 23.16 |
| Total male and female | Total age | J01 Antibacterials for systemic use | 2015 | 21.18 |
| Total male and female | Total age | J01 Antibacterials for systemic use | 2020 | 16.12 |
| Total male and female | Total age | J01 Antibacterials for systemic use | 2021 | 15.83 |
| Total male and female | Total age | J01 Antibacterials for systemic use | 2022 | 17.87 |
| Total male and female | Total age | J01 Antibacterials for systemic use | 2023* | 18.59 |
| Total male and female | Total age | L Antineoplastic and immunomodul. agents | 2006 | 1.22 |
| Total male and female | Total age | L Antineoplastic and immunomodul. agents | 2010 | 1.64 |
| Total male and female | Total age | L Antineoplastic and immunomodul. agents | 2015 | 1.63 |
| Total male and female | Total age | L Antineoplastic and immunomodul. agents | 2020 | 1.91 |
| Total male and female | Total age | L Antineoplastic and immunomodul. agents | 2021 | 2.02 |
| Total male and female | Total age | L Antineoplastic and immunomodul. agents | 2022 | 2.02 |
| Total male and female | Total age | L Antineoplastic and immunomodul. agents | 2023* | 2.06 |
| Total male and female | Total age | M Musculo-skeletal system | 2006 | 18.17 |
| Total male and female | Total age | M Musculo-skeletal system | 2010 | 18.47 |
| Total male and female | Total age | M Musculo-skeletal system | 2015 | 16.14 |
| Total male and female | Total age | M Musculo-skeletal system | 2020 | 13.04 |
| Total male and female | Total age | M Musculo-skeletal system | 2021 | 13.14 |
| Total male and female | Total age | M Musculo-skeletal system | 2022 | 13.14 |
| Total male and female | Total age | M Musculo-skeletal system | 2023* | 12.69 |
| Total male and female | Total age | N Nervous system | 2006 | 19.27 |
| Total male and female | Total age | N Nervous system | 2010 | 16.19 |
| Total male and female | Total age | N Nervous system | 2015 | 16.69 |
| Total male and female | Total age | N Nervous system | 2020 | 16.04 |
| Total male and female | Total age | N Nervous system | 2021 | 16.35 |
| Total male and female | Total age | N Nervous system | 2022 | 16.49 |
| Total male and female | Total age | N Nervous system | 2023* | 16.70 |
| Total male and female | Total age | N02C Antimigraine preparations | 2006 | 1.32 |
| Total male and female | Total age | N02C Antimigraine preparations | 2010 | 1.44 |
| Total male and female | Total age | N02C Antimigraine preparations | 2015 | 1.34 |
| Total male and female | Total age | N02C Antimigraine preparations | 2020 | 1.25 |
| Total male and female | Total age | N02C Antimigraine preparations | 2021 | 1.27 |
| Total male and female | Total age | N02C Antimigraine preparations | 2022 | 1.26 |
| Total male and female | Total age | N02C Antimigraine preparations | 2023* | 1.25 |
| Total male and female | Total age | N06A Antidepressants | 2006 | 5.12 |
| Total male and female | Total age | N06A Antidepressants | 2010 | 5.47 |
| Total male and female | Total age | N06A Antidepressants | 2015 | 5.92 |
| Total male and female | Total age | N06A Antidepressants | 2020 | 5.89 |
| Total male and female | Total age | N06A Antidepressants | 2021 | 5.97 |
| Total male and female | Total age | N06A Antidepressants | 2022 | 5.98 |
| Total male and female | Total age | N06A Antidepressants | 2023* | 6.02 |
| Total male and female | Total age | P Antiparasitics,insecticides,repellents | 2006 | 1.09 |
| Total male and female | Total age | P Antiparasitics,insecticides,repellents | 2010 | 1.16 |
| Total male and female | Total age | P Antiparasitics,insecticides,repellents | 2015 | 1.19 |
| Total male and female | Total age | P Antiparasitics,insecticides,repellents | 2020 | 1.06 |
| Total male and female | Total age | P Antiparasitics,insecticides,repellents | 2021 | 1.15 |
| Total male and female | Total age | P Antiparasitics,insecticides,repellents | 2022 | 1.27 |
| Total male and female | Total age | P Antiparasitics,insecticides,repellents | 2023* | 1.60 |
| Total male and female | Total age | R Respiratory system | 2006 | 19.20 |
| Total male and female | Total age | R Respiratory system | 2010 | 21.00 |
| Total male and female | Total age | R Respiratory system | 2015 | 20.73 |
| Total male and female | Total age | R Respiratory system | 2020 | 18.93 |
| Total male and female | Total age | R Respiratory system | 2021 | 19.10 |
| Total male and female | Total age | R Respiratory system | 2022 | 19.98 |
| Total male and female | Total age | R Respiratory system | 2023* | 20.11 |
| Total male and female | Total age | R03 Drugs for obstruct. airway diseases | 2006 | 8.39 |
| Total male and female | Total age | R03 Drugs for obstruct. airway diseases | 2010 | 9.09 |
| Total male and female | Total age | R03 Drugs for obstruct. airway diseases | 2015 | 8.90 |
| Total male and female | Total age | R03 Drugs for obstruct. airway diseases | 2020 | 8.20 |
| Total male and female | Total age | R03 Drugs for obstruct. airway diseases | 2021 | 8.06 |
| Total male and female | Total age | R03 Drugs for obstruct. airway diseases | 2022 | 8.38 |
| Total male and female | Total age | R03 Drugs for obstruct. airway diseases | 2023* | 8.45 |
| Total male and female | Total age | S Sensory organs | 2006 | 12.24 |
| Total male and female | Total age | S Sensory organs | 2010 | 12.44 |
| Total male and female | Total age | S Sensory organs | 2015 | 11.90 |
| Total male and female | Total age | S Sensory organs | 2020 | 11.26 |
| Total male and female | Total age | S Sensory organs | 2021 | 11.44 |
| Total male and female | Total age | S Sensory organs | 2022 | 11.55 |
| Total male and female | Total age | S Sensory organs | 2023* | 11.87 |
| Source: CBS. | ||||
Table explanation
This table contains figures on the absolute number of persons to whom in the year concerned medicines were dispensed for which the costs are reimbursed under the statutory basic medical insurance. Also, the number of dispensed defined daily doses (DDDs) are presented. The figures are also expressed as a percentage of the total population in the category concerned. The population includes everybody registered in the Personal Records Database (BRP) and living in the Netherlands at some point in the year concerned. Until 2010 the figures also included medicines dispensed to persons registered in the BRP, but no longer resident in the Netherlands.
Medicines provided to persons in hospitals and nursing homes are not included; medicines provided in residential homes for the elderly are included.
Data are broken down by medicine group, age and sex.
Data available from: 2006
Status of the figures:
Figures for 2022 are provisional, figures for previous years are final.
Changes as of December 18, 2024:
- Provisional figures for 2023 have been added, provisional figures of 2022 have been made definite.
- Textual change: the description of drug group Y (Not filled in) has been replaced by Z (Not applicable). However, the underlying resources have remained the same. This category is assigned to products that do not have an ATC code according to the WHO ATC classification system.
When will new figures be published?
New figures will be published in the last quarter of 2025.
Description topics
- Persons with medicines, relative
- Number of persons to whom medicines are dispensed in the year concerned that are reimbursed under the statutory basic medical insurance, expressed as a percentage of the total population of the category concerned registered in the Basic Registration of Persons (BRP) in that year.